ArticleJournal of molecular histology2025
FAM49B mediates tumor progression and poor prognosis of gastric cancer through activating PI3K/AKT pathway.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer is a common malignancy worldwide. It has been shown that the actin cytoskeleton modulator family with sequence similarity 49 member B (FAM49B) is involved in the initiation and spread of malignancies. However, the role of FAM49B is still unknown in gastric cancer. We examined FAM49B expression in gastric cancer and its relationship between the clinical pathological features of gastric cancer patients. Lentiviruses packaged sh-FAM49B were transfected into AGS cells, and the FAM49B overexpression plasmids were transfected into HGC-27 cells to perform loss- or gain-of-function assays. Additionally, AGS cells expressing sh-FAM49B were subcutaneously injected into nude mice. In vitro and in vivo experiments were conducted to investigate the role and mechanism of FAM49B in the progresses of gastric cancer. FAM49B was upregulated in gastric cancer that indicated a poor prognosis of gastric cancer patients. FAM49B enhanced cell viability, the percent of EdU positive cells, invaded cell numbers, the relative protein expression level of PD-L1 and the IL-10 concentration, while reduced the percent of CD8 + T cells and the concentration of IFN-γ in vitro. In tumor-bearing mice, knockdown of FAM49B reduced tumor size and weight, and the protein levels of PD-L1 and IFN-γ. FAM49B promoted the expressions of the PI3K/AKT/mTOR axis in vitro and in vivo. Inhibitory role of the FAM49B knockdown in the above-mentioned progresses was reversed with the treatment of 740Y-P. Therefore, FAM49B promoted the gastric cancer cell growth, invasion and immune escape through the PI3K/AKT/mTOR axis.
Indexed as
Identifiers
40897904What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.